ACS Medicinal Chemistry Letters
Letter
(2) Silhavy, T. J.; Kahne, D.; Walker, S. The bacterial cell envelope.
Cold Spring Harbor Perspect. Biol. 2010, 2, a000414.
Lin, J.; McCurdy, S. P.; Mueller, J. P.; Mullins, L.; Niosi, M.; Noe, M.
C.; Pattavina, D.; Penzien, J.; Plummer, M. S.; Risley, H.; Schuff, B. P.;
Shanmugasundaram, V.; Starr, J. T.; Sun, J.; Winton, J.; Young, J. A.
Novel monobactams utilizing a siderophore uptake mechanism for the
treatment of gram-negative infections. Bioorg. Med. Chem. Lett. 2012,
22, 5989−5994.
(3) Bush, K.; Macielag, M. J. New beta-lactam antibiotics and beta-
lactamase inhibitors. Expert Opin. Ther. Pat. 2010, 20, 1277−1293.
(4) Rossolini, G. M.; Mantengoli, E. Treatment and control of severe
infections caused by multiresistant Pseudomonas aeruginosa. Clin.
Microbiol. Infect. 2005, 11 (Suppl. 4), 17−32.
(5) Nikaido, H.; Vaara, M. Molecular basis of bacterial outer
membrane permeability. Microbiol. Rev. 1985, 49, 1−32.
(6) Fisher, J. F.; Meroueh, S. O.; Mobashery, S. Bacterial resistance to
beta-lactam antibiotics: compelling opportunism, compelling oppor-
tunity. Chem. Rev. 2005, 105, 395−424.
(20) Breuer, H.; Cimarusti, C. M.; Denzel, T.; Koster, W. H.;
Slusarchyk, W. A.; Treuner, U. D. Monobactamsstructure-activity
relationships leading to SQ 26,776. J. Antimicrob. Chemother. 1981, 8
(Suppl. E), 21−28.
(21) Kawabata, K.; Yamanaka, H.; Takasugi, H.; Takaya, T. Studies
2
̂
on I -lactam antibiotics. XIII. Synthesis and structure-activity relation-
2
̂
ships of 7I -(Z)-2-aryl-2-carboxymethoxyiminoacetamido]-3-
(7) Sykes, R. B.; Koster, W. H.; Bonner, D. P. The new
monobactams: chemistry and biology. J. Clin. Pharmacol. 1988, 28,
113−119.
vinylcephalosporins. J. Antibiot. 1986, 39, 404−14.
(22) Yamanaka, H.; Takasugi, H.; Masugi, T.; Kochi, H.; Miyai, K.;
2
̂
Takaya, T. Studies on I -lactam antibiotics. VIII. Structure-activity
(8) Mislin, G. L.; Schalk, I. J. Siderophore-dependent iron uptake
systems as gates for antibiotic Trojan horse strategies against
Pseudomonas aeruginosa. Metallomics 2014, 6, 408−420.
2
̂
relationships of 7I -(Z)-2-carboxymethoxyimino-2-arylacetamido]-3-
cephem-4-carboxylic acids. J. Antibiot. 1985, 38, 1068−76.
(23) Brown, M. F.; Mitton-Fry, M. J.; Han, S.; Lall, M.; Plimmer, M.
S.; Hud, L.; Shanmugasundaram, V.; Starr, J. Monobactams. WO
2012/073138, November 29, 2010.
(24) Mulchande, J.; Martins, L.; Moreira, R.; Archer, M.; Oliveira, T.
F.; Iley, J. The efficiency of C-4 substituents in activating the beta-
lactam scaffold towards serine proteases and hydroxide ion. Org.
Biomol. Chem. 2007, 5, 2617−2626.
(9) Braun, V.; Hantke, K. Recent insights into iron import by
bacteria. Curr. Opin. Chem. Biol. 2011, 15, 328−334.
(10) Foley, T. L.; Simeonov, A. Targeting iron assimilation to
develop new antibacterials. Expert Opin. Drug Discovery 2012, 7, 831−
847.
(11) Noinaj, N.; Guillier, M.; Barnard, T. J.; Buchanan, S. K. TonB-
dependent transporters: Regulation, structure, and function. Annu. Rev.
Microbiol. 2010, 64, 43−60.
(12) Starr, J.; Brown, M. F.; Aschenbrenner, L.; Caspers, N.; Che, Y.;
Gerstenberger, B. S.; Huband, M.; Knafels, J. D.; Lemmon, M. M.; Li,
C.; McCurdy, S. P.; McElroy, E.; Rauckhorst, M. R.; Tomaras, A. P.;
Young, J. A.; Zaniewski, R. P.; Shanmugasundaram, V.; Han, S.
Siderophore receptor-mediated uptake of lactivicin analogues in gram-
negative bacteria. J. Med. Chem. 2014, 57, 3845−3855.
(13) Brown, M. F.; Mitton-Fry, M. J.; Arcari, J. T.; Barham, R.;
Casavant, J.; Gerstenberger, B. S.; Han, S.; Hardink, J. R.; Harris, T.
M.; Hoang, T.; Huband, M. D.; Lall, M. S.; Lemmon, M. M.; Li, C.;
Lin, J.; McCurdy, S. P.; McElroy, E.; McPherson, C.; Marr, E. S.;
Mueller, J. P.; Mullins, L.; Nikitenko, A. A.; Noe, M. C.; Penzien, J.;
Plummer, M. S.; Schuff, B. P.; Shanmugasundaram, V.; Starr, J. T.;
Sun, J.; Tomaras, A.; Young, J. A.; Zaniewski, R. P. Pyridone-
conjugated monobactam antibiotics with gram-negative activity. J. Med.
Chem. 2013, 56, 5541−5552.
(14) Flanagan, M. E.; Brickner, S. J.; Lall, M.; Casavant, J.;
Deschenes, L.; Finegan, S. M.; George, D. M.; Granskog, K.;
Hardink, J. R.; Huband, M. D.; Hoang, T.; Lamb, L.; Marra, A.;
Mitton-Fry, M.; Mueller, J. P.; Mullins, L. M.; Noe, M. C.; O’Donnell,
J. P.; Pattavina, D.; Penzien, J. B.; Schuff, B. P.; Sun, J.; Whipple, D. A.;
Young, J.; Gootz, T. D. Preparation, Gram-negative antibacterial
activity, and hydrolytic stability of novel siderophore-conjugated
monocarbam diols. ACS Med. Chem. Lett. 2011, 2, 385−390.
(15) Page, M. G.; Dantier, C.; Desarbre, E. In vitro properties of
BAL30072, a novel siderophore sulfactam with activity against
multiresistant gram-negative bacilli. Antimicrob. Agents Chemother.
2010, 54, 2291−2302.
(25) Sendai, M.; Hashiguchi, S.; Tomimoto, M.; Kishimoto, S.;
Matsuo, T.; Kondo, M.; Ochiai, M. Chemical modification of
sulfazecin. Synthesis of 4-(substituted methyl)-2-azetidinone-1-sulfonic
acid derivatives. J. Antibiot. (Tokyo) 1985, 38, 346−371.
(26) Slusarchyk, W. A.; Dejneka, T.; Gougoutas, J.; Koster, W. H.;
Kronenthal, D. R.; Malley, M.; Perri, M. G.; Routh, F. L.; Sundeen, J.
2
̂
E.; et al. I -Lactam synthesis: chemospecific sulfonation and cyclization
2
̂
of the I -hydroxyvaline nucleus. Tetrahedron Lett. 1986, 27, 2789−92.
(27) Mattingly, P. G.; Miller, M. J. Titanium trichloride reduction of
substituted N-hydroxy-2-azetidinones and other hydroxamic acids. J.
Org. Chem. 1980, 45, 410−15.
2
̂
(28) Cimarusti, C. M.; Sykes, R. B. Monocyclic I -lactam antibiotics.
Med. Res. Rev. 1984, 4, 1−24.
(29) Han, S.; Zaniewski, R. P.; Marr, E. S.; Lacey, B. M.; Tomaras, A.
P.; Evdokimov, A.; Miller, J. R.; Shanmugasundaram, V. Structural
basis for effectiveness of siderophore-conjugated monocarbams against
clinically relevant strains of Pseudomonas aeruginosa. Proc. Natl. Acad.
Sci. U.S.A. 2010, 107, 22002−22007.
(30) Starr, J.; Brown, M. F.; Aschenbrenner, L.; Caspers, N.; Che, Y.;
Gerstenberger, B. S.; Huband, M.; Knafels, J. D.; Lemmon, M. M.; Li,
C.; McCurdy, S. P.; McElroy, E.; Rauckhorst, M. R.; Tomaras, A. P.;
Young, J. A.; Zaniewski, R. P.; Shanmugasundaram, V.; Han, S.
Siderophore receptor-mediated uptake of lactivicin analogues in gram-
negative bacteria. J. Med. Chem. 2014, 57, 3845−3855.
(31) Turnidge, J. D. The pharmacodynamics of beta-lactams. Clin.
Infect. Dis. 1998, 27, 10−22.
(32) Kim, A.; Crandon, J.; Gorseth, E.; Blinn, C.; Patey, S.; Kutschke,
A.; Chen, A.; Rooney, M.; Benenato, K.; Ehmann, D.; Eakin, A.;
Nicolau, D. In vivo pharmacodynamics of a siderophore-conjugated
monocarbam in Pseudomonas aeruginosa (PA): Assessing the risk of
attenuated efficacy. Abstracts of Papers, Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), Washington DC,
Sep 5−9, 2014; American Society of Microbiology: Washington, DC,
2014.
(16) Barbachyn, M. R.; Tuominen, T. C. Synthesis and structure-
activity relationships of monocarbams leading to U-78608. J. Antibiot.
(Tokyo) 1990, 43, 1199−1203.
(17) McPherson, C. J.; Aschenbrenner, L. M.; Lacey, B. M.; Fahnoe,
K. C.; Lemmon, M. M.; Finegan, S. M.; Tadakamalla, B.; O’Donnell, J.
P.; Mueller, J. P.; Tomaras, A. P. Clinically relevant Gram-negative
resistance mechanisms have no effect on the efficacy of MC-1, a novel
siderophore-conjugated monocarbam. Antimicrob. Agents Chemother.
2012, 56, 6334−6342.
(18) Woulfe, S. R.; Miller, M. J. The synthesis of substituted 3(S)-
(acylamino)-2-oxo-1-azetidinyl]thio]acetic acids. J. Org. Chem. 1986,
51, 3133−3139.
(19) Mitton-Fry, M. J.; Arcari, J. T.; Brown, M. F.; Casavant, J. M.;
Finegan, S. M.; Flanagan, M. E.; Gao, H.; George, D. M.;
Gerstenberger, B. S.; Han, S.; Hardink, J. R.; Harris, T. M.; Hoang,
T.; Huband, M. D.; Irvine, R.; Lall, M. S.; Megan Lemmon, M.; Li, C.;
F
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX